JP2011148786A - Pharmaceutical liquid composition - Google Patents

Pharmaceutical liquid composition Download PDF

Info

Publication number
JP2011148786A
JP2011148786A JP2010286882A JP2010286882A JP2011148786A JP 2011148786 A JP2011148786 A JP 2011148786A JP 2010286882 A JP2010286882 A JP 2010286882A JP 2010286882 A JP2010286882 A JP 2010286882A JP 2011148786 A JP2011148786 A JP 2011148786A
Authority
JP
Japan
Prior art keywords
sodium
water
liquid composition
palatability
physical fatigue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010286882A
Other languages
Japanese (ja)
Inventor
Kenji Tsunoda
健司 角田
Yasutaka Iizuka
泰貴 飯塚
Masatoshi Takahashi
正寿 高橋
Hidekazu Mafune
英一 真船
Norio Kokatsu
規生 小勝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Healthcare Co Ltd
Original Assignee
Daiichi Sankyo Healthcare Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Healthcare Co Ltd filed Critical Daiichi Sankyo Healthcare Co Ltd
Priority to JP2010286882A priority Critical patent/JP2011148786A/en
Publication of JP2011148786A publication Critical patent/JP2011148786A/en
Pending legal-status Critical Current

Links

Landscapes

  • Non-Alcoholic Beverages (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical liquid composition for enhancing palatability in physical exhaustion. <P>SOLUTION: The pharmaceutical liquid composition for internal use includes L-glutamic acid or its salt and inosinic acid or its salt and has improved palatability in physical exhaustion. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

本発明は、肉体疲労時における嗜好性を向上させた内服用医薬液剤組成物に関する。   The present invention relates to a pharmaceutical solution composition for internal use with improved palatability during physical fatigue.

従来から、運動などによる肉体疲労時には甘味の強い物が好まれることが経験的に知られ、特定濃度のアスコルビン酸で酸味を持たせた場合にも肉体疲労時の嗜好性が向上することが開示されている(特許文献1参照)。また、特定濃度のショ糖に、特定の有機酸を特定濃度に添加した場合にも肉体疲労時の嗜好性が向上した内服液剤が得られ(特許文献2参照)、ショ糖の0.15〜0.6モル濃度相当の甘味度を有する糖アルコール等を配合した液剤も嗜好性が良好であることが開示されている(特許文献3参照)。   Conventionally, it has been empirically known that strongly sweet foods are preferred during physical fatigue due to exercise, etc., and it is disclosed that palatability during physical fatigue is improved even when soured with a specific concentration of ascorbic acid (See Patent Document 1). In addition, when a specific organic acid is added to a specific concentration of sucrose, an oral solution with improved palatability during physical fatigue can be obtained (see Patent Document 2). It is disclosed that a liquid preparation containing a sugar alcohol having a sweetness equivalent to 0.6 molar concentration also has good palatability (see Patent Document 3).

一方、グルタミン酸摂取がラットの水泳時間を延長すること(例えば、特許文献4参照)、分岐鎖アミノ酸(バリン、ロイシン、イソロイシン)が運動負荷後の血中乳酸濃度を軽減すること(例えば、特許文献5参照)が開示され、アミノ酸に抗疲労作用のあることが知られている。なお、アミノ酸の一種であるグルタミン酸、核酸の一種であるイノシン酸やグアニル酸は代表的な旨味物質としてよく知られており、これらは単独で使うよりも組み合わせた方が、旨味が一層増すことも知られている(非特許文献1参照)。   On the other hand, glutamic acid intake extends the swimming time of rats (for example, see Patent Document 4), and branched chain amino acids (valine, leucine, isoleucine) reduce blood lactate concentration after exercise (for example, Patent Documents) 5) is disclosed, and amino acids are known to have anti-fatigue effects. In addition, glutamic acid, which is a kind of amino acid, and inosinic acid and guanylic acid, which are kinds of nucleic acids, are well known as typical umami substances, and these may be further enhanced by combining them rather than using them alone. It is known (see Non-Patent Document 1).

しかし、アミノ酸の抗疲労作用が、肉体疲労時におけるアミノ酸の嗜好性にも関与するかどうかは不明である。   However, it is unclear whether the anti-fatigue action of amino acids is also related to the preference of amino acids during physical fatigue.

特開2000-93134号公報JP 2000-93134 A 特開2000-333651号公報JP 2000-333651 A 特開平11-171777号公報Japanese Patent Laid-Open No. 11-171777 特開平4-164028号公報Japanese Patent Laid-Open No. 4-164028 特開2006-16358号公報JP 2006-16358

渡辺誠、「調味料[1]うま味調味料(2)」、食品と容器、2004、Vol.45 No.8Makoto Watanabe, “Seasoning [1] Umami Seasoning (2)”, Food and Containers, 2004, Vol.45 No.8

肉体疲労時の栄養補給効能を有する内服用医薬液剤および/または肉体疲労回復効果を有する内服用医薬液剤組成物において、それらの嗜好性を向上させることは、当該効能および/または当該効果を高めることに繋がることから、合目的的な手段となり得る。   Improving the palatability of an internal-use pharmaceutical solution and / or an internal-use pharmaceutical solution composition having an effect of recovering physical fatigue improves the efficacy and / or the effect. Can lead to a purposeful means.

しかし、上述のアスコルビン酸を添加した液剤の安定性は不充分であるという課題があり、また、ショ糖を配合する場合には嗜好性は増すかもしれないが、カロリー過剰摂取という課題があった。そのため、アスコルビン酸やショ糖を含有せず、かつ、肉体疲労時に嗜好性の高まる液剤組成物を実現することが本発明の課題である。   However, there is a problem that the stability of the liquid preparation containing the above-mentioned ascorbic acid is insufficient, and when sucrose is added, the preference may increase, but there is a problem of excessive intake of calories. . Therefore, it is an object of the present invention to realize a liquid composition that does not contain ascorbic acid or sucrose and has increased palatability during physical fatigue.

本発明者らは、上記の課題を解決するために、まず、上述のごとく抗疲労作用のあるグルタミン酸について、肉体疲労時の嗜好性の有無を調べた。その結果、疲労負荷前後でグルタミン酸の嗜好性は全く変化しないどころか、疲労負荷前後のいずれもグルタミン酸を添加していない液剤の方が、嗜好性が高くなるという予想外の結果となった。   In order to solve the above-mentioned problems, the present inventors first examined the presence or absence of palatability during physical fatigue of glutamic acid having anti-fatigue action as described above. As a result, the preference of glutamic acid did not change at all before and after the fatigue load, but an unexpected result that the preference without the addition of glutamic acid before and after the fatigue load was higher.

さらに、鋭意研究を重ねた結果、グルタミン酸含有液剤にイノシン酸をさらに添加した場合、疲労負荷前(平常時)の嗜好性が若干増加するという結果が得られ、さらに驚くべきことに、肉体疲労時では嗜好性がさらに増加するという、グルタミン酸単独の結果からでは予想もつかない事実を見出し、本発明を完成するに至った。   Furthermore, as a result of extensive research, when inosinic acid was further added to a glutamic acid-containing solution, the result was that the preference before fatigue loading (normal) was slightly increased. Then, the fact that the palatability was further increased, the fact that could not be expected from the result of glutamic acid alone, was found, and the present invention was completed.

すなわち、本発明は、以下に記すとおりである。
(1)L−グルタミン酸またはその塩とイノシン酸またはその塩とを含有する、肉体疲労時における嗜好性を向上させた内服用医薬液剤組成物、
(2)L−グルタミン酸ナトリウムとイノシン酸ナトリウムとを含有する、肉体疲労時における嗜好性を向上させた内服用医薬液剤組成物、ならびに、
(3)ビタミン類をさらに含有する、前記(1)または(2)に記載の組成物。
That is, the present invention is as described below.
(1) A medicinal liquid composition for internal use which comprises L-glutamic acid or a salt thereof and inosinic acid or a salt thereof and which has improved palatability during physical fatigue,
(2) A pharmaceutical solution composition for internal use containing sodium L-glutamate and sodium inosinate with improved palatability during physical fatigue, and
(3) The composition according to (1) or (2), further comprising vitamins.

本発明により、肉体疲労時の嗜好性を向上させた内服用医薬液剤が得られた。肉体疲労時の栄養補給および/または疲労回復効果を有する医薬液液剤の嗜好性が向上すると、当該効能および/または当該効果をより一層高めることにも繋がるため有用である。   According to the present invention, a pharmaceutical solution for internal use with improved palatability during physical fatigue was obtained. Improvement in the preference of a pharmaceutical solution having a nutritional supplement and / or fatigue recovery effect during physical fatigue is useful because it also leads to further enhancement of the efficacy and / or the effect.

肉体疲労前後のL-グルタミン酸ナトリウムを添加した液剤の嗜好性を示す図である。It is a figure which shows the palatability of the liquid agent which added the sodium L-glutamate before and after physical fatigue. 肉体疲労前後のイノシン酸ナトリウムを添加した液剤の嗜好性を示す図である。It is a figure which shows the palatability of the liquid agent which added sodium inosinate before and after physical fatigue. 肉体疲労前後のL-グルタミン酸ナトリウムおよびイノシン酸ナトリウムを添加した液剤の嗜好性を示す図である。It is a figure which shows the palatability of the liquid agent which added the sodium L-glutamate and sodium inosinate before and after physical fatigue.

本発明に使用されるグルタミン酸またはその塩としては、L-グルタミン酸、L-グルタミン酸塩酸塩、L-グルタミン酸カリウム、L-グルタミン酸ナトリウム等が挙げられ、それらは医薬品添加物事典2005に収載されている。   Examples of glutamic acid or a salt thereof used in the present invention include L-glutamic acid, L-glutamic acid hydrochloride, potassium L-glutamate, sodium L-glutamate and the like, and these are listed in Pharmaceutical Additives Dictionary 2005.

本発明に使用されるイノシン酸またはその塩としては、5'-イノシン酸ジナトリウム(イノシン酸ナトリウム)、5'-イノシン酸ジカリウム(イノシン酸カリウム)等が挙げられ、前者は医薬品添加物事典2005に収載されている。   Examples of inosinic acid or a salt thereof used in the present invention include disodium 5′-inosinate (sodium inosinate), dipotassium 5′-inosinate (potassium inosinate), and the like. It is listed.

本発明の医薬液剤組成物中に添加されるL-グルタミン酸またはその塩、および、イノシン酸またはその塩の添加濃度は、特に限定されないが、いずれも好ましくは、0.1〜10mMである。   The addition concentration of L-glutamic acid or a salt thereof and inosinic acid or a salt thereof added to the pharmaceutical solution composition of the present invention is not particularly limited, but both are preferably 0.1 to 10 mM.

本発明に使用されるビタミン類としては、ビタミンB1、例えば、チアミン、硝酸チアミン、塩酸チアミン、ベンフォチアミン、その他のビタミンB1誘導体等;ビタミンB2、例えば、リボフラビン、リン酸リボフラビンナトリウム、酪酸リボフラビン等;ビタミンB6、例えば、ピリドキシン、ピリドキサル、ピリドキサミン及びこれらのリン酸又は塩酸塩等;ビタミンB12、例えば、コバラミン、シアノコバラミン、メチルコバラミン等;ビタミンBT、例えば、カルニチン塩化物;ニコチン酸アミド等が挙げられる。これらのうち、より好ましくは、ビタミンB1の塩または誘導体、ビタミンB2、ビタミンB6、あるいはニコチン酸アミドである。これらビタミン類の配合量にも特に制限はなく、従来公知の量で含めることができる。   The vitamins used in the present invention include vitamin B1, such as thiamine, thiamine nitrate, thiamine hydrochloride, benfotiamine, other vitamin B1 derivatives, etc .; vitamin B2, such as riboflavin, sodium riboflavin phosphate, riboflavin butyrate, etc. Vitamin B6 such as pyridoxine, pyridoxal, pyridoxamine and their phosphates or hydrochlorides; vitamin B12 such as cobalamin, cyanocobalamin, methylcobalamin, etc .; vitamin BT such as carnitine chloride; nicotinamide . Of these, more preferred are salts or derivatives of vitamin B1, vitamin B2, vitamin B6, or nicotinamide. There is no restriction | limiting in particular also in the compounding quantity of these vitamins, It can contain in a conventionally well-known quantity.

本発明の組成物には、上記成分に加えて、本発明の効果を損なわない範囲で、慣用の添加剤、例えば、糖、糖アルコール、甘味料、生薬・漢方薬類、ミネラル類、カフェイン類、アミノ酸類、有機酸類、精油成分、溶解補助剤、pH調整剤、界面活性剤、保存剤、香料、着色剤、矯味剤等を含めることができる。   In the composition of the present invention, in addition to the above components, conventional additives such as sugars, sugar alcohols, sweeteners, herbal medicines / Chinese medicines, minerals, caffeine are used within the range not impairing the effects of the present invention. , Amino acids, organic acids, essential oil components, solubilizers, pH adjusters, surfactants, preservatives, fragrances, colorants, flavoring agents, and the like.

本発明の組成物は、公知の方法で製造することができる。例えば、各成分を適量の精製水で溶解した後、pH調整し、次いで、残りの精製水を加えて容量調整をすることにより製造することができる。また、必要に応じて、濾過及び減菌処理をすることもできる。   The composition of this invention can be manufactured by a well-known method. For example, it can be produced by dissolving each component with an appropriate amount of purified water, adjusting the pH, and then adjusting the volume by adding the remaining purified water. In addition, filtration and sterilization treatment can be performed as necessary.

表1に記載の成分および分量をとり、日局製剤総則「液剤」の項に準じて液剤を製造する。   Taking the components and amounts shown in Table 1, a liquid preparation is produced according to the section “General Liquid Preparation”.

表2に記載の成分および分量をとり、日局製剤総則「液剤」の項に準じて液剤を製造する。   Taking the components and amounts shown in Table 2, a liquid preparation is produced according to the section “General Liquid Preparation”.

(試験例)
(1)被検物質
L-グルタミン酸ナトリウムは協和発酵バイオ(株)製のものを、イノシン酸ナトリウムは味の素(株)のものを使用した。
(Test example)
(1) Test substance
Sodium L-glutamate was manufactured by Kyowa Hakko Bio Co., Ltd., and sodium inosinate was used by Ajinomoto Co., Inc.

(2)使用動物
ddY系雄性マウス6週齢を日本エスエルシー(株)から購入し、温度20〜26℃、湿度30〜70%、照明時間7時〜19時に制御された飼育室内でマウス用ポリカーボネート製ケージに入れ、市販のFR-2飼料(フナバシファーム製)を自由摂取させ1週間馴化させた。
(2) Animals used
ddY male mice 6 weeks old were purchased from Japan SLC Co., Ltd., and placed in a cage made of polycarbonate for mice in a breeding room controlled at a temperature of 20 to 26 ° C, humidity of 30 to 70%, and lighting time of 7:00 to 19:00. Then, a commercially available FR-2 feed (manufactured by Funabashi Farm) was freely ingested and acclimated for one week.

(3)試験方法
2週目に、実験は1ケージあたり3匹とし各群6ケージで行った。飲料用水として注射用水の入った給水瓶と、注射用水に被検物質としてL-グルタミン酸ナトリウム単独、イノシン酸ナトリウム単独またはグルタミン酸ナトリウムとイノシン酸ナトリウムを添加した給水瓶を、すなわち、2つの給水瓶をケージ中に設置した。1週間の各瓶の飲水量を測定し、次式によって嗜好率(%)を算出した。
(3) Test method
On the second week, the experiment was conducted with 6 animals per group, with 3 animals per cage. A water bottle containing water for injection as drinking water and a water bottle containing sodium L-glutamate alone, sodium inosinate alone or sodium glutamate and sodium inosinate as test substances in water for injection, that is, two water bottles Installed in cage. The amount of water consumed in each bottle for one week was measured, and the preference rate (%) was calculated by the following formula.

式中、「総飲水量」とは、試験中にマウスが飲んだ、注射用水の量と各被検物質を添加した注射用水の量を合計した値である。例えば、試験中、マウスが注射用水を50g、被検物質を添加した注射用水を30g飲んだ場合、嗜好率は、次のとおり算出される。   In the formula, the “total amount of drinking water” is a value obtained by summing the amount of water for injection and the amount of water for injection added with each test substance, which the mouse drank during the test. For example, when the mouse dries 50 g of water for injection and 30 g of water for injection added with a test substance during the test, the preference rate is calculated as follows.

3週目に該マウスを自動回転かご((有)永澤理化学機器店製)に入れ、2.4回転/分のスピードで毎日3時間1週間にわたり強制歩行させ、1週間の飲水量をもとに運動負荷後の嗜好率とした。   In the third week, place the mouse in an automatic rotating basket (manufactured by Nagasawa Riken Equipment Store), and forcibly walk for 3 hours a week every day at a speed of 2.4 rpm, exercising based on the amount of water consumed for one week. The preference rate after loading.

(4)試験結果1
被検物質としてL-グルタミン酸ナトリウムを用いた場合の試験結果を図1に示す。いずれも、各群18匹の平均値である。図1の結果より、L-グルタミン酸ナトリウムを添加した注射用水の方が、無添加の注射用水よりも嗜好率が低いことがわかった。また、この結果は運動負荷前後でも変化は認められなかった。
(4) Test result 1
The test results when sodium L-glutamate is used as the test substance are shown in FIG. All are average values of 18 animals in each group. From the results of FIG. 1, it was found that the water for injection added with sodium L-glutamate had a lower preference rate than the water for injection without addition. In addition, no change was observed in the results before and after exercise.

(5)試験結果2
被検物質としてイノシン酸ナトリウムを用いた場合の試験結果を図2に示す。いずれも、18匹の平均値である。図2の結果より、イノシン酸ナトリウムを添加した注射用水の方が、無添加の注射用水よりも嗜好率が若干低いことがわかった。また、この結果は運動負荷前後でも変化は認められなかった。
(5) Test result 2
FIG. 2 shows the test results when sodium inosinate is used as the test substance. All are average values of 18 animals. From the results of FIG. 2, it was found that the preference rate was slightly lower in the water for injection to which sodium inosinate was added than in the water for injection without addition. In addition, no change was observed in the results before and after exercise.

(6)試験結果3
被検物質としてグルタミン酸ナトリウムとイノシン酸ナトリウムを用いた場合の試験結果を図3に示す。いずれも、各群18匹の平均値である。図3の結果より、グルタミン酸ナトリウムとイノシン酸ナトリウムを添加した注射用水の方が、無添加の注射用水よりも嗜好率が高いことがわかる。さらに、運動負荷前よりも運動負荷後の方が嗜好率はさらに高くなるということもわかる。
(6) Test result 3
FIG. 3 shows the test results when sodium glutamate and sodium inosinate are used as test substances. All are average values of 18 animals in each group. From the results of FIG. 3, it can be seen that the water for injection added with sodium glutamate and sodium inosinate has a higher preference rate than the water for injection without addition. It can also be seen that the preference rate is higher after exercise than before exercise.

Claims (3)

L−グルタミン酸またはその塩とイノシン酸またはその塩とを含有する、肉体疲労時における嗜好性を向上させた内服用医薬液剤組成物。   A pharmaceutical liquid composition for internal use which has improved palatability during physical fatigue, comprising L-glutamic acid or a salt thereof and inosinic acid or a salt thereof. L−グルタミン酸ナトリウムとイノシン酸ナトリウムとを含有する、肉体疲労時における嗜好性を向上させた内服用医薬液剤組成物。   A pharmaceutical liquid composition for internal use which has improved palatability during physical fatigue, comprising sodium L-glutamate and sodium inosinate. ビタミン類をさらに含有する、請求項1または2に記載の組成物。
The composition according to claim 1 or 2, further comprising vitamins.
JP2010286882A 2009-12-25 2010-12-24 Pharmaceutical liquid composition Pending JP2011148786A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010286882A JP2011148786A (en) 2009-12-25 2010-12-24 Pharmaceutical liquid composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009295814 2009-12-25
JP2009295814 2009-12-25
JP2010286882A JP2011148786A (en) 2009-12-25 2010-12-24 Pharmaceutical liquid composition

Publications (1)

Publication Number Publication Date
JP2011148786A true JP2011148786A (en) 2011-08-04

Family

ID=44536135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010286882A Pending JP2011148786A (en) 2009-12-25 2010-12-24 Pharmaceutical liquid composition

Country Status (1)

Country Link
JP (1) JP2011148786A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04164028A (en) * 1990-02-19 1992-06-09 Miwon Co Ltd Fatigue restorative mainly comprising monosodium glutamate, and use thereof
JPH11171777A (en) * 1997-09-30 1999-06-29 Taisho Pharmaceut Co Ltd Internal liquid preparation for physical exhaustion
JP2000093134A (en) * 1998-09-24 2000-04-04 Taisho Pharmaceut Co Ltd Liquid agent for internal use in physical fatigue
JP2000333651A (en) * 1999-05-26 2000-12-05 Taisho Pharmaceut Co Ltd Oral liquid formulation for physical fatigue
JP2006016358A (en) * 2004-07-02 2006-01-19 Dai Ichi Seiyaku Co Ltd Anti-fatigue formulation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04164028A (en) * 1990-02-19 1992-06-09 Miwon Co Ltd Fatigue restorative mainly comprising monosodium glutamate, and use thereof
JPH11171777A (en) * 1997-09-30 1999-06-29 Taisho Pharmaceut Co Ltd Internal liquid preparation for physical exhaustion
JP2000093134A (en) * 1998-09-24 2000-04-04 Taisho Pharmaceut Co Ltd Liquid agent for internal use in physical fatigue
JP2000333651A (en) * 1999-05-26 2000-12-05 Taisho Pharmaceut Co Ltd Oral liquid formulation for physical fatigue
JP2006016358A (en) * 2004-07-02 2006-01-19 Dai Ichi Seiyaku Co Ltd Anti-fatigue formulation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6014028753; 日本味と匂学会誌 Vol.13, No.3, 200612, pp.331-334 *
JPN6014028754; 日本女子大学紀要 理学部 Vol.15, 2007, pp.35-44 *
JPN6014028755; 日本味と匂学会誌 Vol.10, No.3, 200312, pp.531-534 *
JPN6014028756; 日畜会報 Vol.67, No.6, 1996, pp.561-566 *
JPN6014028757; Neuroscience Research Vol.65, Supplement 1, 200909, p.S211, right *

Similar Documents

Publication Publication Date Title
EP1767201B1 (en) Nutrient composition and composition for prevention/mitigation of digestive tract depression
RU2009110912A (en) MEANS AND FOOD FOR PREVENTION / REDUCING MANIFESTATIONS OF FUNCTIONAL DIGESTION
US20160250169A1 (en) Compositions and methods for improving cognitive function
JP2017155052A (en) Amino acid compositions
JP4484058B2 (en) Fatigue recovery food composition
CN109715168A (en) For treating the composition being still drank after a night
US9993447B2 (en) Systems and methods for increasing agmatine cellular uptake by oral administration
JP5586816B2 (en) Composition containing zinc compound
JP2007197363A (en) Nutritional supplement
JP5162812B2 (en) Zinc-containing composition for oral administration
JP2003169642A (en) Beverage containing highly branched cyclic dextrin
JP4929628B2 (en) Zinc-containing oral solution
JP2006306846A (en) Copper compound-incorporated composition
CN1708240A (en) Ergogenic multivitamin-mineral energy supplement for the prevention of muscle fatigue
JP5794900B2 (en) Pharmaceutical solution composition
JP2011148786A (en) Pharmaceutical liquid composition
JP5167594B2 (en) Composition for internal use liquid containing copper compound
JP2002338473A (en) Anti-fatigue composition
JP2006131618A (en) Zinc compound-formulated composition
Ochiai et al. Effect of a fermented brown rice extract on the gastrointestinal function in methotrexate-treated rats
JP2002173442A (en) Antifatigue composition
KR20110011233A (en) Composition for reducing fatigue containing chito-oligosaccharide
JP5011776B2 (en) Copper compound composition
JP4815798B2 (en) Copper-containing composition for oral administration
JP2018121535A (en) Beverage

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140708

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140901